

---

# Index

## A

Acute pyelonephritis, 206–210  
Antibiotic resistance, 22, 143, 220, 229  
Antibiotic susceptibility testing, 227  
Antibiotics, 16, 19, 22, 74, 78, 102, 112, 141, 143, 192, 247  
Antibody, 8, 39, 44, 112, 153, 156, 163, 168–171, 176, 221  
Anti-malarial, 244, 247  
Antimicrobials, 22, 41, 147, 163, 222, 230–232, 234  
Artesunate, 244, 245  
*Aspergillus*, 28, 29, 32, 34, 35, 39–41, 43, 45, 46, 169, 181  
Autoinflammatory bone disease, 99, 100

## B

B cell, 44, 112, 168, 176, 208  
Bacillary angiomatosis, 159, 162  
*Bartonella henselae*, 160–162  
*Bartonella quintana*, 160–162  
Biological, 103, 152, 183, 208, 224  
Bisphosphonates, 103, 104  
Bocavirus, 196, 198  
Bone and joint infection, 33, 156

## C

Carriage, 16, 17, 19, 208, 209  
Cell-mediated immunity, 118, 185  
Central nervous system infection, 133, 135, 242  
Chagas disease, 3–6, 8, 9  
*Chlamydia trachomatis*, 109–115, 117–119  
Circumcision, 213, 216  
Colonisation, 142, 146  
Coronavirus, 195, 196, 198  
Cystitis, 206, 212

## D

Diarrhoea, 13, 15, 19, 172, 196

## E

Enteropathogenic *E. coli*, 74, 76  
ESBL, 22

## F

FEAST trial, 245–248  
Flavivirus, 133, 138, 139  
Fluid resuscitation, 245  
Fungal infection, 28–31, 34, 35, 39, 40, 45, 47, 48, 154, 169

## G

Gastroenteritis, 13–17, 20, 246  
Gonorrhoea, 220–225, 227, 229–234

## H

Healthcare-related infections, 141  
Helminth, 3, 5, 6  
Henipavirus, 192–194, 198  
Herpes simplex virus, 133–135, 137, 154  
Heuristics, 82, 83, 85, 87, 89, 94  
Host–pathogen interaction, 29, 48, 206  
Human metapneumovirus, 194, 195, 198

## I

Immunocompromise, 19, 28, 31, 44, 47, 48, 159, 169, 198  
Immunodeficiency, 15, 29, 41, 45, 155, 162, 167, 231  
Influenza, 82, 83, 85, 93, 191, 193, 195, 199  
Innate immunity, 168, 207, 208, 210  
Interferon regulatory factors, 208–210

## L

Lymphadenopathy, 41, 161–164, 181

## M

Madura foot, 179  
Mass drug administration, 5, 6, 9

Molecular diagnosis, 43, 47, 160, 163, 164, 183, 192, 198, 199, 227, 228  
 Monoclonal, 103, 116, 152, 153, 155, 156  
 MRSA, 142, 145  
 Multidrug resistance, 41  
 Mycoplasma, 114, 137, 138

## N

Neonatal conjunctivitis, 110, 117  
 Neonatal pneumonitis, 110, 117  
 Nipah, 193, 194, 198  
 Non-steroidal anti-inflammatory drugs, 102, 103  
 Nucleic acid amplification tests, 115, 116, 226–228, 234

## O

Oral rehydration therapy, 74, 76, 78

## P

Paediatric, 22, 103, 152, 172, 173, 197, 244, 246, 248  
 Parasite, 8, 15, 110, 134, 242, 244  
 Parechovirus, 196–198  
 Parinaud oculoglandular syndrome, 162  
 Pathogenesis, 13, 15, 48, 74, 79, 111, 137, 152, 160, 164, 184, 220  
 Pelvic inflammatory disease, 110, 114, 225  
 Penicillin-resistant *Streptococcus pneumoniae*, 124  
*Plasmodium falciparum*, 134, 241, 243, 244  
 Polyomaviruse, 155, 197, 198  
 Preventative, 156, 220, 222, 233  
 Prophylaxis, 28, 35, 43, 45–48, 118, 141, 143, 145–148, 172, 233  
 Pseudomembranous colitis, 65, 66

## R

Randomised clinical trial, 8, 17, 47, 78, 92, 102, 103, 137, 152, 163, 247  
 Receptor, 110–112, 152, 153, 185, 207–209, 220  
 Recurrent infection, 167, 171, 210, 213  
 Risk perception, 82, 83, 85  
 Rituximab, 152, 155, 157

## S

*Salmonella*, 13–16, 153  
 Sexual networks, 220, 224, 225  
 Sexually transmitted infections, 113, 114, 222–224, 229, 232–234  
 Shock, 243, 247, 248  
 Social marketing, 95  
 Surgical complication, 142  
 Surgical site infection, 141, 142, 147

## T

T cell, 9, 29, 46, 100, 112, 118, 155, 168, 170, 172, 176  
 Toll-like receptors, 209, 210  
 Tumour necrosis factor, 103, 152, 153

## U

Urethritis, 110, 114, 225, 226

## V

Vaccine concerns, 82, 83, 88  
 Vaccine pain, 89, 93  
 Virulence, 110, 160, 184, 186, 206–208, 210, 220

## Z

Zinc, 77, 78  
 Zygomycosis, 29, 34